Artificial Intelligence | News | Insights | AiThority
[bsfp-cryptocurrency style=”widget-18″ align=”marquee” columns=”6″ coins=”selected” coins-count=”6″ coins-selected=”BTC,ETH,XRP,LTC,EOS,ADA,XLM,NEO,LTC,EOS,XEM,DASH,USDT,BNB,QTUM,XVG,ONT,ZEC,STEEM” currency=”USD” title=”Cryptocurrency Widget” show_title=”0″ icon=”” scheme=”light” bs-show-desktop=”1″ bs-show-tablet=”1″ bs-show-phone=”1″ custom-css-class=”” custom-id=”” css=”.vc_custom_1523079266073{margin-bottom: 0px !important;padding-top: 0px !important;padding-bottom: 0px !important;}”]

Exscientia Hires Director of Data Engineering to Scale up its AI Drug Discovery Platform

Following a highly successful year and several drug discovery milestones using its flagship AI platform, Exscientia is pleased to welcome Andrew Douglas as the new Director of Data Engineering.

Andrew joins Exscientia from Winton Capital, a global investment management and data science company, where he led the design and creation of platforms, algorithms and models to automate data processing, analyse data and predict outcomes as a core element of the firm’s strategic investment approach.

Andrew has 10+ years’ experience in data engineering and in developing systems that support the functioning of AI-powered approaches. At Exscientia, he will leverage his expertise to streamline, scale up the company’s data systems and automated processes alongside supporting the AI to perform design work. This will enable Exscientia’s drug discovery teams to increase productivity and therefore the quality of drug candidates generated through the Centaur Chemist platform.

Read More: MaxQ Accelerates AI Performance with Intel

Related Posts
1 of 31,657

“We’re thrilled to welcome Andrew to the team,” says Adrian Schreyer, CTO at Exscientia. “This is a very exciting time for us, as we are rapidly expanding our talent in computer science and drug discovery in anticipation of rapid growth, so this timing could not have been better.”

Since Exscientia’s inception in 2012, the company has grown exponentially securing six major pharma collaborations (Evotec, Roche, GSK, Sanofi, Sumitomo and Sunovion) and rapidly growing its proprietary pipeline of drugs. Earlier this year, it has secured a $26 million Series B investment. The company is led by an industry-recognised executive team with years of experience at leading firms like Pfizer, GSK and Goldman Sachs, and several industry awards amongst them. It is now on a path to ramp up its technology capabilities.

Read More: [24] Appoints Digital Transformation Expert as Chief Operating Officer

Andrew commented: “What drew me to Exscientia’s mission is that its use of technology is strongly driven by objective results and their impact on drug discovery productivity. There is also a clear recognition at Exscientia of the synergy possible between human expertise and machine intelligence and a motivation to really make a difference to patients’ lives. I very much look forward to applying my experience in data volume, variety, velocity and veracity acquired through my time in the financial sector into drug discovery and working with a world-class team to deliver these goals.”

Read More: AiThority Interview Series with Dan Bladen, CEO, Chargifi

Leave A Reply

Your email address will not be published.